SCHEMBL16145800

SCHEMBL16145800

CC1(C)OC[C@H]2O[C@@H](OC(=O)c3ccccc3)[C@H](NC(=O)OCc3ccccc3)[C@@H](O)[C@@H]2O1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ BCHE P06276 3/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CPB1 P15086 2/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CTSL P07711 1/20 0.35
▸ CTSS P25774 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15012280 0.89 L3MBTL1 (0.46) ALDH1A1GAATSHRL3MBTL1CPB1
SCHEMBL16146137 0.86 ALDH1A1 (0.42) ALDH1A1GAATSHRCPB1KMT2A
SCHEMBL16153931 0.82 LMNA (0.46) ALDH1A1TSHRL3MBTL1KMT2A
SCHEMBL11269209 0.81 L3MBTL1 (0.44) L3MBTL1KMT2ACTSL
SCHEMBL5308210 0.81 L3MBTL1 (0.54) ALDH1A1L3MBTL1KMT2A
SCHEMBL1836110 0.81 L3MBTL1 (0.54) ALDH1A1L3MBTL1KMT2A
SCHEMBL16146024 0.79 L3MBTL1 (0.45) ALDH1A1BCHEL3MBTL1
SCHEMBL16153921 0.79 L3MBTL1 (0.39) ALDH1A1GAABCHEL3MBTL1KMT2A
SCHEMBL10832365 0.78 L3MBTL1 (0.45) ALDH1A1BCHEL3MBTL1
SCHEMBL8822971 0.76 L3MBTL1 (0.41) ALDH1A1GAATSHRL3MBTL1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303363-A1 Preparation and Use of Isolactosamine and Intermediates therefor GLYCOM A/S (DK) 2014-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303363-A1 Preparation and Use of Isolactosamine and Intermediates therefor GALE, B4GALT1, GNE ALDH1A1 889/4885GAA 382/4885SMN1; SMN2 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback